Babus and junket the Estados Unidos the lobby anti-India
Several Civil Society Groups Have Written To The Minister Of Health Expressing Concern For The Participation Of Senior Officials Of The Ministry And The (CDSCO) At A Meeting In The United States Organized By A Pressure Group Of The American Biopharmaceutical Industry.
The 13th Annual BioPharma &healthcaresummitscheduledforthursdaywasorganizedbytheuschamberofcommerce.uuandindia(),whichisdominatedbytransnationalcorporations.theletteraddressedtotheministernotedthatmanyofthesecompanieswerealsomembersofthepharmaceuticalindustryresearchgroupoftheunitedstates(phrma),whosepressuregroupsoftenattacktheintellectualpropertyregimeofindia.andthemedicinesregulations.
theagendaoftheusaicsummit' S Is Dominated By Transnational Corporations And Their Interests. This Type Of Conference Is Often Used To Lobby And Promote The Interests Of The Industry. De Los Participation Policy Makers And Regulators In Those Meetings Sends A Signal Error And Increases The Vulnerability Of Government Of India Corporate Undue Influence Corporate Transnational Drug In The Formulation Of Policies And Regulations India, Said The Charter.
The Letter Pointed Out That The Time Of Participation Of The Ministry Of Health Was Especially Charged In Light Of The Recent Special Report 301 Of The Trade Representative Of The United States, Where For The 27th Consecutive Year, India Was Placed On The Priority Surveillance List For Its Alleged Bad Execution Of Intellectual Property Rules. India Has Continued To Reject The Report That Qualifies It As Unilateral And Insisted That India's Intellectual Property Laws Comply Fully With The WTO Regulations.
The PhRMA Presentation ' S The USTR Contained Several Complaints And Illegitimate Accusations Against India And Sought Regulatory Changes Through The Back Door To Block The Entry Of Generics, Noted The Letter." Many Of The Biopharmaceutical Industry's Demands Are Reflected In Special Report 301 Of 2019 , That Spreads Wrong Lies And Propaganda Against India, With Aim To Undermine The Image Of India's Generic Industry," He Added. He Declared The Letter.
He Also Made Reference To The Statements Made By The Secretary Of Commerce Of The United States, Ross, On May 7, About The Market Access Barriers Facing The US Companies, Which Also Mentioned The Indian Price Controls On Medical Devices And Pharmaceutical Products. How ' Obstacles ' For American Companies.
When Referring To Media Reports That The Government Could Relax The Regulation Of Pricing Of Medical Devices And Dilute The Price Limit And In Response To The Pressure Of The United States, Civil Society Groups Urged The Government Not To Succeed In The Pressure Of The United States. They Also Urged The Minister To Take Measures To Prevent The Undue Influence Of United States Industry Associations Such As PhRMA And USAIC In The Formulation Of Indian Policies.